ASLAN Pharmaceuticals Ltd.

General Information
Business:

 

(Note: Our ordinary shares are currently listed on the Taipei Exchange, or TPEx. On April 13, 2018, the last reported sale price of our ordinary shares on the TPEx was NT$47.30 per share, or approximately $1.61 per share, based on an exchange rate of NT$29.30 to $1.00. ur shares have been traded since June 1, 2017.)

We are a clinical-stage oncology-focused biopharmaceutical company based in Singapore developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Our Asia development platform is designed to enable us to accelerate the development of drugs to treat these diseases. Our portfolio is comprised of four product candidates which target: validated growth pathways applied to new patient segments; novel immune checkpoints; and novel cancer metabolic pathways.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 47
Founded: 2014
Contact Information
Address 83 Clemenceau Avenue #12-03 UE Square, Singapore 239920
Phone Number +65 6222 4235.
Web Address http://www.aslanpharma.com
View Prospectus: ASLAN Pharmaceuticals Ltd.
Financial Information
Market Cap $269.8mil
Revenues $0 mil (last 12 months)
Net Income $-39.9 mil (last 12 months)
IPO Profile
Symbol ASLN
Exchange NASDAQ
Shares (millions): 6.0
Price range $7.03 - $7.03
Est. $ Volume $42.2 mil
Manager / Joint Managers Leerink Partners/ Piper Jaffray
CO-Managers BTIG/ H.C. Wainwright/ CLSA
Expected To Trade: 5/4/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change